Vascular Biogenics Ltd. (NASDAQ:VBLT) was up 3.1% on Monday . The stock traded as high as $4.11 and last traded at $4.04, with a volume of 116,110 shares changing hands. The stock had previously closed at $3.92.

Several equities research analysts have weighed in on VBLT shares. Zacks Investment Research cut shares of Vascular Biogenics from a “hold” rating to a “sell” rating in a research report on Wednesday, June 22nd. Piper Jaffray Cos. reissued a “buy” rating and set a $14.00 price target on shares of Vascular Biogenics in a research report on Tuesday, June 7th. Chardan Capital reaffirmed a “buy” rating on shares of Vascular Biogenics in a research report on Tuesday, June 7th. HC Wainwright assumed coverage on shares of Vascular Biogenics in a research report on Tuesday, June 28th. They issued a “buy” rating and a $11.00 target price for the company. Finally, Roth Capital reaffirmed a “buy” rating and issued a $22.00 target price on shares of Vascular Biogenics in a research report on Thursday, June 9th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $13.67.

The firm’s market capitalization is $96.08 million. The stock’s 50-day moving average price is $4.11 and its 200 day moving average price is $3.73.

Vascular Biogenics (NASDAQ:VBLT) last announced its quarterly earnings results on Monday, August 15th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.09. Equities analysts anticipate that Vascular Biogenics Ltd. will post ($0.64) earnings per share for the current year.

Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.